Michael B. Hoffman - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 4, 2026
Michael B. Hoffman has filed 2 SEC Form 4 filings across 2 companies in the last 90 days - buying. Lifetime open-market purchases: $3.95M.
Profile
Michael B. Hoffman holds the role of Chairman and CEO at Translational Development Acquisition Corp. (TDAC). Hoffman's filing history also covers Annovis Bio, Inc. (ANVS). Hoffman has reported 11 insider filings with the SEC since 2025. The most recent filing was in May 2026.
| Role | Chairman and CEO, Director |
|---|---|
| Notability | 40/100 |
Board memberships
- Translational Development Acquisition Corp.
- Annovis Bio, Inc.
Reported roles
- Chairman and CEO
- Director
Track Record
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| Total purchases tracked | 9 |
|---|
Trading Pattern
InsiderAlpha's records for Michael B. Hoffman go back to 2025: 11 primary Form 4 filings, an average of 5.5 per year. The typical open-market purchase is $303K (13 buys totaling $3.95M). The largest single buy on record is $2.00M of ANVS in 2025. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role Michael B. Hoffman has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Chairman and CEO, Director at Translational Development Acquisition Corp. (TDAC) - 1 filing, 2026
- Director at Annovis Bio, Inc. (ANVS) - 10 filings, 2025 to 2026
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-22 | ANVS | Annovis Bio, Inc. | P - Open-market purchase | 54.9K | $1.90 | $104K |
| 2026-05-22 | ANVS | Annovis Bio, Inc. | P - Open-market purchase | 18.8K | $1.80 | $34K |
| 2026-05-22 | ANVS | Annovis Bio, Inc. | P - Open-market purchase | 2.6K | $1.75 | $4K |
| 2026-04-03 | ANVS | Annovis Bio, Inc. | P - Open-market purchase | 713.8K | $2.10 | $1.50M |
| 2025-11-25 | ANVS | Annovis Bio, Inc. | P - Open-market purchase | 28.1K | $4.15 | $117K |
| 2025-11-25 | ANVS | Annovis Bio, Inc. | P - Open-market purchase | 415 | $4.14 | $2K |
| 2025-11-25 | ANVS | Annovis Bio, Inc. | P - Open-market purchase | 9.2K | $3.85 | $35K |
| 2025-11-25 | ANVS | Annovis Bio, Inc. | P - Open-market purchase | 1.5K | $4.13 | $6K |
| 2025-11-21 | ANVS | Annovis Bio, Inc. | P - Open-market purchase | 10.0K | $3.50 | $35K |
| 2025-11-21 | ANVS | Annovis Bio, Inc. | P - Open-market purchase | 10.0K | $3.49 | $35K |
| 2025-11-18 | ANVS | Annovis Bio, Inc. | P - Open-market purchase | 15.0K | $2.11 | $32K |
| 2025-11-12 | ANVS | Annovis Bio, Inc. | P - Open-market purchase | 975.6K | $2.05 | $2.00M |
| 2025-08-29 | ANVS | Annovis Bio, Inc. | A - Grant or award | 5.0K | $2.30 | $12K |
| 2025-08-29 | ANVS | Annovis Bio, Inc. | A - Grant or award | 5.0K | $2.29 | $11K |
| 2025-08-29 | ANVS | Annovis Bio, Inc. | A - Grant or award | 5.0K | $2.28 | $11K |
| 2025-08-19 | ANVS | Annovis Bio, Inc. | A - Grant or award | 1.1K | $2.57 | $3K |
| 2025-08-19 | ANVS | Annovis Bio, Inc. | A - Grant or award | 5.5K | $2.58 | $14K |
| 2025-08-19 | ANVS | Annovis Bio, Inc. | A - Grant or award | 5.3K | $2.59 | $14K |
| 2025-08-19 | ANVS | Annovis Bio, Inc. | A - Grant or award | 6.7K | $2.60 | $17K |
| 2025-06-13 | ANVS | Annovis Bio, Inc. | A - Grant or award | 1 | $2.83 | $3 |
Companies - Last 90 Days
- Translational Development Acquisition Corp. (TDAC) - 1 filing, last 2026-05-29
- Annovis Bio, Inc. (ANVS) - 1 filing, last 2026-05-22
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies Michael B. Hoffman has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Maria-Luisa Maccecchini - $200K of ANVS open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- Andrew J. Mills
- Charles N. Mills
- Mink Brook Asset Management LLC
- Shankh Mitra
- MITSUI SUMITOMO INSURANCE CO LTD
- Arturo R. Moreno
- Matthew T. Moroun
- Dustin A. Moskovitz
Frequently Asked Questions
Who is Michael B. Hoffman?
Michael B. Hoffman holds the role of Chairman and CEO at Translational Development Acquisition Corp. (TDAC). Hoffman's filing history also covers Annovis Bio, Inc. (ANVS). Hoffman has reported 11 insider filings with the SEC since 2025. The most recent filing was in May 2026.…
How many SEC Form 4 filings has Michael B. Hoffman submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Michael B. Hoffman been buying or selling stock?
Recorded transactions: 13 open-market purchases ($3.95M) and 0 open-market sales across all tracked filings.
How accurate is Michael B. Hoffman's historical track record?
Across 9 tracked purchases, Michael B. Hoffman averaged no 30-day data yet with a win rate pending. InsiderAlpha rates the track record at –/5 stars.
Where can I see all of Michael B. Hoffman's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live Michael B. Hoffman profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.